2025 Annual Report
Annual Report
ECETOC publishes a framework for the risk assessment of plastic additives
Press Release

ECETOC publishes a framework for the risk assessment of plastic additives

Part 1 sets out the fundamental elements, from problem formulation to risk characterisation.Brussels, 22 July 2026. The ECETOC Plastic Additives Task Force has published the first of two peer...
January 2026 news from the Sec Gen
News

January 2026 news from the Sec Gen

Dear colleagues and friends,As we begin a new year, I would like to thank you for your continued engagement and trust in ECETOC. 2026 promises to be an exciting and dynamic year, and I am pleased...
HSSD Tool

HSSD Tool

This software was developed by a consortium of partners to facilitate the uptake of novel approaches to estimate aquatic threshold concentrations (e.g. the concentration at which 5% of the species are exposed above their EC50, HC5).
The Human Exposure Assessment Tools Database (heatDB)

The Human Exposure Assessment Tools Database (heatDB)

heatdb is a public directory of exposure data sources as well as available tools for exposure
NanoApp

NanoApp

ECETOC’s NanoApp is a tool designed to define the boundaries of sets of similar nanoforms and to generate a justification for the REACH registration.
Targeted Risk Assessment (TRA)

Targeted Risk Assessment (TRA)

The Targeted Risk Assessment (TRA) estimates exposures to workers, consumers and the environment that arise during a series of events.
Immunotoxicity assessment: Addressing Challenges and Advancing Methodologies [Workshop → Task Force]​

Immunotoxicity assessment: Addressing Challenges and Advancing Methodologies [Workshop → Task Force]​

Why?Regulatory assessment of immunotoxic properties of chemicals is a complex and challenging task​ Limited regulatory guidance exists​ Lack of industry and regulatory knowledge​...
Chronic fish case studies towards an IATA

Chronic fish case studies towards an IATA

Why?Hazard and safety assessments for the pelagic compartment often rely on in vivo studies using a single fish species, raising ethical concerns and uncertainty in terms of extrapolation....
Estimating the environmental release of Synthetic Polymeric Microparticles from Products

Estimating the environmental release of Synthetic Polymeric Microparticles from Products

Why?REACH restriction: SPM use restricted; emissions reporting required by May 2027. Gap: No analytical methods available to measure SPM emissions. Solution: Draft SPERC-based approac...
09.11.2018

Doubts cast on link between PSPs and lung cancer in humans

Experimental study findings in which chronic inhalation of poorly soluble particles (PSPs) gives rise to lung tumours in rats have been questioned in terms of their relevance and applicability to humans, according to an article in the journal Regulatory Toxicology and Pharmacology. The phenomenon, known as ‘lung overload’, was described and discussed in ECETOC’s Technical Report 122.


Highlights

  • Inhalation of high concentrations of PSPs leads to pro-inflammatory responses and pulmonary toxicity in all species.
  • In humans, inhalation exposure to PSPs is not associated with development of lung tumours.
  • Interstitialisation of PSPs in humans is a key factor in the difference in pathological response between rats and humans.
  • The rat model is sensitive and valuable for detecting early and thresholded responses of inflammatory markers.

Abstract

In 2013, an ECETOC Task Force evaluated scientific understanding of the ‘lung overload’ hypothesis. As there is no evidence that humans develop lung tumours following exposure to poorly soluble particles (PSPs), emphasis was given to the observed higher sensitivity and specificity of rat lung responses and potential impacts of this on human risk assessment.

Key arguments and outcomes are summarised here, together with discussion of additional findings published since 2013. Inhalation exposure to PSPs in all species is associated with localised pulmonary toxicity initiated by a persistent pro-inflammatory response to particle deposition. Events in the rat indicate a plausible adverse outcome pathway for lung tumour development following exposure to PSPs under overload conditions. A different particle lung translocation pattern compared to rats make humans less sensitive to developing comparable lung overload conditions and appears to also preclude tumour formation, even under severe and prolonged exposure conditions. Evidence continues to suggest that the rat lung model is unreliable as a predictor for human lung cancer risk. However, it is a sensitive model for detecting various thresholded inflammatory markers, with utility for non-neoplastic risk assessment purposes. It is noteworthy that preventing inflammatory rat lung responses will also inhibit development of neoplastic outcomes.